NCT00233766View on ClinicalTrials.gov

Evaluation of Two Reduced Sirolimus Doses in Treatment of de Novo Coronary Artery Lesions (REDOX)

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

60

Participants

Timeline

Start Date

September 30, 2002

Primary Completion Date

December 31, 2007

Study Completion Date

December 31, 2007

Conditions

Coronary Artery Disease

Interventions

DEVICE

Bx VELOCITY Stent containing 45% and 70% of Sirolimus dose

Trial Locations (1)

Unknown

Instituto Dante Pazzanese de Cardiologia, São Paulo

Sponsors

Lead Sponsor

Cordis Corporation

All Listed Sponsors

lead

Cordis Corporation

INDUSTRY

NCT00233766 - Evaluation of Two Reduced Sirolimus Doses in Treatment of de Novo Coronary Artery Lesions (REDOX) | Biotech Hunter | Biotech Hunter